234 related articles for article (PubMed ID: 32087138)
21. Glypican 3 as a Serum Marker for Hepatoblastoma.
Zhou S; O'Gorman MR; Yang F; Andresen K; Wang L
Sci Rep; 2017 Apr; 7():45932. PubMed ID: 28378832
[TBL] [Abstract][Full Text] [Related]
22. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Value of Serum Biomarkers in Combined Hepatocelluar-Cholangiocarcinoma.
Chen J; Li Y; Yu G
J Coll Physicians Surg Pak; 2020 Mar; 30(3):263-267. PubMed ID: 32169133
[TBL] [Abstract][Full Text] [Related]
24. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
25. [The value of serum glypican-3 level in aided diagnosis of patients with primary hepatocellular carcinoma].
Tang XY; Wang YC; Lu RQ; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):998-1002. PubMed ID: 32907292
[No Abstract] [Full Text] [Related]
26. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma.
Zhang Q; Xiao Q; Lin Z; Ying X; Li Z; Lin JM
Clin Biochem; 2010 Aug; 43(12):1003-8. PubMed ID: 20444424
[TBL] [Abstract][Full Text] [Related]
27. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
28. Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma.
Zhao Y; Wang M; Cui C; Zhang L; Liao F; Li H; Wu X
Cancer Biomark; 2015; 15(5):677-83. PubMed ID: 26406957
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.
Liu JW; Zuo XL; Wang S
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3655-73. PubMed ID: 26502856
[TBL] [Abstract][Full Text] [Related]
30. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Gomaa SH; Abaza MM; Elattar HA; Amin GA; Elshahawy DM
Arab J Gastroenterol; 2020 Dec; 21(4):224-232. PubMed ID: 32891543
[TBL] [Abstract][Full Text] [Related]
31. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.
Yan D; He Q; Chen Y; Wang L; Zhang X
J Clin Lab Anal; 2011; 25(2):113-7. PubMed ID: 21438004
[TBL] [Abstract][Full Text] [Related]
32. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
35. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
36. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
37. Serological tumor markers of hepatocellular carcinoma: a meta-analysis.
Hussein TD
Int J Biol Markers; 2015 Feb; 30(1):e32-42. PubMed ID: 25450646
[TBL] [Abstract][Full Text] [Related]
38. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1.
Shu H; Li W; Shang S; Qin X; Zhang S; Liu Y
Discov Med; 2017 Mar; 23(126):163-168. PubMed ID: 28472609
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.
Qiao SS; Cui ZQ; Gong L; Han H; Chen PC; Guo LM; Yu X; Wei YH; Ha SA; Kim JW; Jin ZT; Li S; Peng JR; Leng XS
Hepatogastroenterology; 2011; 58(110-111):1718-24. PubMed ID: 21940340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]